AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...

The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...

This milestone underscores our commitment to providing cost-effective, high-quality biosimilars to patients ... and European Medicines Agency (EMA). The safety profile of YESINTEK was similar ...

This article explores the challenges and highlights actionable telehealth solutions that enhance access to care, particularly for mothers at higher risk of postpartum depression. Maternal health ...